Giordanetto Fabrizio, Tyrchan Christian, Ulander Johan
D.E. Shaw Research , 120W 45th Street, New York, New York 10036, United States.
Medicinal Chemistry, Respiratory and Inflammation, Innovative Medicines and Early Development Biotech Unit, Astrazeneca, Mölndal , Pepparedsleden 1, SE-431 83 Mölndal, Sweden.
ACS Med Chem Lett. 2017 Jan 18;8(2):139-142. doi: 10.1021/acsmedchemlett.7b00002. eCollection 2017 Feb 9.
Design strategies centered on intramolecular hydrogen bonds are sometime used in drug discovery, but their general applicability has not been addressed beyond scattered examples or circumstantial evidence. A total of 1053 matched molecular pairs where only one of the two molecules is able to form an intramolecular hydrogen bond via monatomic transformations have been identified across the ChEMBL database. These pairs were used to investigate the effect of intramolecular hydrogen bonds on biological activity. While cases of extreme, conflicting variation of effect emerge, the mean biological activity difference for a pair is close to zero and does not exceed ±0.5 log biological activity for over 50% of the analyzed sample.
以分子内氢键为核心的设计策略有时会用于药物研发,但除了一些零散的例子或间接证据外,其普遍适用性尚未得到充分探讨。在ChEMBL数据库中,总共识别出1053对匹配分子对,其中两个分子中只有一个能够通过单原子转化形成分子内氢键。这些分子对被用于研究分子内氢键对生物活性的影响。虽然出现了一些极端的、相互矛盾的效应变化情况,但对于一对分子而言,其平均生物活性差异接近零,并且在超过50%的分析样本中,生物活性差异不超过±0.5 log生物活性。